Key result
Omicron-era COVID-19 linked to ~94% lower case fatality in pulmonary hypertension.
Why the study?
Patients with pulmonary hypertension have experienced high COVID-19-associated mortality, but trends in mortality rates over time have not been fully characterized.
Observational (n=392)
Yes
Odds Ratio: 0.064 (95% CI 0.016–0.189)
Absolute Event Rate: 1.6% vs 20.1%
COVID-19 case fatality in pulmonary hypertension declined markedly with Omicron; extends pre-Omicron registry data but should not yet change practice.
Patients with pulmonary hypertension (PH) have been among those affected heavily by the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Early case series reported case fatality rates ranging from 19–45% in small series of 11–70 patients with PH who contracted COVID-19 [1–4]. A prospective series of 211 French patients with various forms of PH, who developed COVID-19 between February 2020 and April 2021, found an overall case fatality rate of 24.6% [5]. In patients with pulmonary hypertension, the mortality rate associated with COVID-19 has declined sharply with the emergence of the Omicron variants
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2023) conducted an observational in Pulmonary hypertension and COVID-19 (n=392). COVID-19 infection during the Omicron era (Jan-Oct 2022) vs. COVID-19 infection during the pre-Omicron era (Jan 2020-Dec 2021) was evaluated on COVID-19-associated case fatality rate (OR 0.064, 95% CI 0.016-0.189). The case fatality rate of patients with pulmonary hypertension who contracted COVID-19 declined substantially from 20.1% in the pre-Omicron era to 1.6% in the Omicron era (OR 0.064).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: